We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > rucaparib

News List

BDR Pharma launches generic Rucaparib to treat advanced ovarian and prostate cancers expresspharma
May 31, 2021
BDR Pharmaceutical launched BDPARIB (Rucaparib) to treat advanced ovarian and prostate cancers.
FDA Approves Liquid Biopsy NGS Companion Diagnostic Test americanpharmaceuticalreview
November 20, 2020
The U.S. Food and Drug Administration (FDA) approved the liquid biopsy next-generation sequencing-based FoundationOne Liquid CDx test (Foundation Medicine, Inc.) as a companion diagnostic device for multiple additional biomarkers detected in ...
Clovis’ PARP inhibitor Rubraca under EU review in maintenance setting pharmatimes
July 10, 2018
European regulators have agreed to review Clovis’ application to expand the use of its PARP inhibitor Rubraca in the region.